middle.news

PYC Therapeutics Confirms Safety Milestone for PKD Drug Candidate PYC-003

9:40am on Friday 19th of December, 2025 AEDT Biotechnology
Read Story

PYC Therapeutics Confirms Safety Milestone for PKD Drug Candidate PYC-003

9:40am on Friday 19th of December, 2025 AEDT
Key Points
  • PYC-003 safe and well tolerated up to 4 mg/kg in healthy volunteers
  • No serious adverse events reported in Phase 1a/1b Part A
  • Dosing commenced in PKD patients for Part B of the study
  • Repeat dosing in patients planned for first half of 2026
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about PYC
OPEN ARTICLE